Showing 1931-1940 of 2216 results for "".
- Four Years Running: Alastin Leads in Growthhttps://modernaesthetics.com/news/four-years-running-alastin-leads-in-growth/2473044/Alastin Skincare®, Inc. is the Fastest Growing Brand in the US Professional Skincare Market for the fourth year in a row. That’s according to the latest rankings from consulting and research firm Kline Group's 2020 Professional Skincare: US Market Analysis and Opportunitie
- Merz and Candela Announce New Collabhttps://modernaesthetics.com/news/merz-and-candela-announce-new-collab/2473041/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales reprentatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally integr
- Are COVID-19 Vaccines Risky for Dermal Filler Patients? Dermatologists Weigh the Existing Evidencehttps://modernaesthetics.com/news/are-covid-19-vaccines-risky-for-dermal-filler-patients-dermatologists-weigh-the-existing-evidence/2473039/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Are COVID-19 Vaccines Safe for Filler Patients?https://modernaesthetics.com/news/facial-fillers-and-covid-19-vaccines-is-there-a-risk-for-adverse-reactions/2473036/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Expert Sets Record Straight on COVID-19 Vaccine/Fillers “Risk”https://modernaesthetics.com/news/expert-sets-record-straight-on-covid-19-vaccinefillers-risk/2473033/When FDA officials reviewed the data for Moderna’s COVID-19 vaccine, a data point garnered some attention. There seemed to be at least a temporal association between treatment with dermal fillers and non-serious adverse reactions to the vaccine in three study subjects. Modern Aesth
- 2020 in Reviewhttps://modernaesthetics.com/news/2020-in-review-1/2473031/• The AmSpa Aesthetic Safety Council (AASC), designed to help the American Med Spa Association (AmSpa) further its goal of promoting compliance, safety, and profitability throughout the medical aesthetic industry, has launched. Even in the midst of the international COVI
- Developing Story: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://modernaesthetics.com/news/developing-story-abbvies-allergan-wins-trade-secret-case-against-evolus/2473030/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- Revance Names Nashville Its New Homehttps://modernaesthetics.com/news/revance-names-nashville-its-new-home/2473029/Revance Therapeutics is relocating to Nashville. In conjunction with Tennessee Gov. Bill Lee and Tennessee Department of Economic and Community Development (TNECD) Commissioner Bob Rolfe, the company says it is leaving its current home in Silicon Valley’
- HydraFacial To Go Public After SPAC Dealhttps://modernaesthetics.com/news/hydrafacial-to-go-public-after-spac-deal/2473028/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Revance Update: FDA Defers Approval of DaxibotulinumtoxinA Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://modernaesthetics.com/news/revance-update-fda-defers-approval-of-daxibotulinumtoxina-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2473027/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r